Nimorazole

Nimorazole
Clinical data
AHFS/Drugs.com	International Drug Names
ATC code	P01AB06 (WHO) QP51AA06 (WHO);
Identifiers
	IUPAC name 4-[2-(5-nitro-1H-imidazol-1-yl)ethyl]morpholine;
CAS Number	6506-37-2;
PubChem CID	23009;
ChemSpider	21533;
UNII	469ULX0H4G;
KEGG	D07352 ;
CompTox Dashboard (EPA)	DTXSID1057795 ;
ECHA InfoCard	100.026.723
Chemical and physical data
Formula	C9H14N4O3
Molar mass	226.236 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1COCCN1CCN2C=NC=C2[N+](=O)[O-];
	InChI InChI=1S/C9H14N4O3/c14-13(15)9-7-10-8-12(9)2-1-11-3-5-16-6-4-11/h7-8H,1-6H2; Key:MDJFHRLTPRPZLY-UHFFFAOYSA-N;
	(verify)

Nimorazole (INN) is a nitroimidazole anti-infective.[1] It is also being investigated for the treatment of head and neck cancer.[2][3]

References

Roy RB, Laird SM, Heasman L (August 1975). "Treatment of trichomoniasis in the female. A comparison of metronidazole and nimorazole". The British Journal of Venereal Diseases. 51 (4): 281–4. doi:10.1136/sti.51.4.281. PMC 1046566. PMID 1098732.
Henk JM, Bishop K, Shepherd SF (January 2003). "Treatment of head and neck cancer with CHART and nimorazole: phase II study". Radiotherapy and Oncology. 66 (1): 65–70. doi:10.1016/S0167-8140(02)00284-0. PMID 12559522.
Clinical trial number NCT01507467 for "IAEA-HypoX. Accelerated Radiotherapy With or Without Nimorazole in Squamous Cell Carcinoma of the Head and Neck" at ClinicalTrials.gov

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.